Lundbeck Canada

Last updated: 13.02.2014

lundbeck.jpgIn 1995, Lundbeck opened the Canadian office and began the process of gaining approval to sell Cipramil®, or Celexa® as it is known in Canada. For the first few years in Canada, a small group of employees worked to build awareness of the company.  At the time, there were two established Lundbeck products available; Clopixol® and Fluanxol®, both for the treatment of schizophrenia which are still widely used today.  The team forged strong, solid relationships with Canadian physicians so that by the time Celexa® (citalpram) received regulatory approval from HealthCanadain 1999, the foundation had been built.  The company grew quickly to its current size of over 180 employees.

The company’s long term vision also meant developing Canadian-based clinical research activity with a CNS focus, which continues to grow as Canadian researchers conduct trials with currently available Lundbeck products as well as with innovative treatments that are not yet available in Canada.

1000 rue de la Gauchetière
Ouest Bureau 500
H3B 4W5
Montréal Québec

Phone +1 514 844 8515
Fax +1 514 844 5495



We use cookies to ensure that we give you the best experience on our site. For more info click here